代谢综合征合并慢性肾脏病的预防与管理
本文综述了代谢综合征合并慢性肾脏病(CKD)的预防与管理策略。代谢综合征以肥胖、高血压、血脂异常和高血糖为特征,在CKD患者中常见。大型随机试验证实五类药物具有肾脏和/或心血管保护作用,包括RAS抑制剂、SGLT2抑制剂、他汀类、非奈利酮和司美格鲁肽,联合使用可最大化获益,但仍需进一步试验降低残余风险。
要点
- RAS抑制剂和SGLT2抑制剂可延缓多数CKD患者肾病进展并减少心衰并发症
- 他汀类降低LDL-C和动脉粥样硬化风险,但对肾脏结局无临床意义影响
- 2型糖尿病合并白蛋白尿性CKD患者,非奈利酮和司美格鲁肽具心肾获益,司美格鲁肽还可减重
核心结论
- 代谢综合征可能介导了CKD中部分心肾风险,五类 pharmacotherapies 应联合使用以最大化获益,但非治愈手段,仍需进一步试验降低残余心肾风险。
研究设计与样本
- 综述类文章,汇总大型随机试验证据,未报告具体检索范围与样本量。
主要发现
- RAS抑制剂和SGLT2抑制剂可延缓多数CKD患者肾病进展并减少心衰并发症。
- 他汀类降低LDL-C和动脉粥样硬化疾病风险,对肾脏结局无临床意义影响。
- 2型糖尿病合并白蛋白尿性CKD患者中,非奈利酮和司美格鲁肽具心肾获益,司美格鲁肽还可减重。
临床怎么用
- 对CKD合并代谢综合征患者,应考虑联合使用RAS抑制剂、SGLT2抑制剂、他汀类,以及符合条件的患者使用非奈利酮和司美格鲁肽。
局限性
- 联合治疗仍不能治愈CKD,残余心肾风险需进一步试验探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of patients with chronic kidney disease (CKD) requires implementation of prevention and management strategies that reduce the risk of kidney failure and CKD-associated cardiovascular risk. Metabolic syndrome is characterized by obesity, high blood pressure, dyslipidemia, and hyperglycemia, and it is common among patients with CKD. Large-scale randomized trials have led to significant advances in the management of CKD, with 5 pharmacotherapies now proven to be nephroprotective and/or cardioprotective in certain types of patients. Renin-angiotensin system inhibitors and sodium-glucose cotransporter 2 inhibitors slow kidney disease progression and reduce heart failure complications for most patients with CKD. In addition, statin-based regimens reduce low-density lipoprotein cholesterol and lower the risk of atherosclerotic disease (with no clinically meaningful effect on kidney outcomes). For patients with type 2 diabetes and albuminuric CKD, the nonsteroidal mineralocorticoid receptor antagonist finerenone and the glucagon-like peptide-1 receptor agonist semaglutide also confer cardiorenal benefits, with semaglutide additionally effective at reducing weight. Together, these randomized data strongly suggest that metabolic syndrome mediates some of the cardiorenal risk observed in CKD. Considered separately, the trials help elucidate which components of metabolic syndrome influence the pathophysiology of kidney disease progression and which separately modify risk of atherosclerotic and nonatherosclerotic cardiovascular outcomes. As we predict complementary and different mechanisms of nephroprotection and cardioprotection for these different interventions, it seems logical that they should be deployed together to maximize benefits. Even when combined, however, these therapies are not a cure, so further trials remain important to reduce the residual cardiorenal risks associated with CKD.
引用
- Zhu D, Judge PK, Wanner C, et al. The prevention and management of chronic kidney disease among patients with metabolic syndrome. Kidney Int. 2025. PMID: 39986466. doi:10.1016/j.kint.2024.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。